(NaturalNews) Consumers constantly are told how complicated it is to get a new drug on the market. After all, researchers have to jump through all sorts of hoops to assure safety before new therapies are approved for the public, right?
It turns out they may be missing some of those hoops or not jumping through some of the most important ones.
In fact, huge red flags are being raised about how drugs are tested and approved in two new studies, including one just published in the May 4th issue of the Journal of the American Medical Association (JAMA).
A case in point: it turns out that only about half of the new prescription medications pushed onto the market over the last decade had the proper data together for the U.S. Food and Drug Administration –yet the FDA approved them anyhow.
The information in question is known specifically ascomparative effectiveness data. And it is – or should be – a very big deal when it comes to deciding whether a drug should be approved and sold to the public.
According to the Institute of Medicine, comparative effectiveness data is defined as the “generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition or to improve the delivery of care.”
In other words, how does a new drug stack up against other treatments – is it more beneficial, safer, or does it have more potential dangers?
Read the full article here: http://www.naturalnews.com/032279_Big_Pharma_fraud.html